ArticleScience advances2026
A spatially resolved implantable microdevice for multiplexed in situ screening of engineered cellular therapies in solid tumors.
Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The clinical translation of cellular immunotherapies for solid tumors remains limited by the lack of adequate tools to evaluate therapeutic function within the native tumor microenvironment. Here, we demonstrate a miniaturized implantable microdevice (IMD) capable of spatially resolving and multiplexing the delivery and screening of multiple T cell therapies directly within live tumors. This customizable IMD is comprised of discrete fibrin-filled reservoirs that can be independently loaded with distinct immune cell formulations, which enables spatially confined release and region-specific immune-tumor interactions within the same tumor mass. Using this platform in glioblastoma xenografts, we simultaneously delivered EGFR-targeting CAR-T cells and control T cells and analyzed adjacent tissues via IHC-based quantitative image analysis and multiplexed immunofluorescence. The perireservoir region adjacent to CAR-T cell reservoirs exhibited dense CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.